<ueqbl class="dpqya"></ueqbl>

南宫NG28医药

Be the most trusted biotech company

2019-07-31

Henlius Innovative Anti-HER2 Monoclonal Antibody HLX22 Have Dosed First Patient for Its Phase 1 Study
2019-07-12

Henlius Novel Anti-PD-1 Antibody HLX10 Received Clinical Trial Approval in Taiwan for the Treatment of Hepatitis B
2019-07-04

Henlius Has Completed the Phase 3 Study of Its Adalimumab Injection HLX03
2019-06-21

EMA Accepted First “China-Developed” Biosimilar - Henlius HLX02 Marketing Authorization Application for Review
2019-06-17

Henlius Presented Data of Two Anti-inflammatory Candidates at EULAR 2019
2019-06-10

Henlius Attends BIO 2019
2019-04-25

Henlius Trastuzumab HLX02 Filed New Drug Application
2019-04-03

Shanghai Henlius Set to Increase Awareness of Biosimilars, in Partnership with Nature Research
2019-03-22

Global Clinical Medicine Affairs Department Needs You to Join!